Market
Outcome of vision loss study related to Ozempic by end of 2025?
2
Novo Nordisk•Ozempic•European Medicines Agency•EMA•Harvard University•Eli Lilly•Mounjaro•Britons•Wegovy
Resolution / Starting Odds
Confirms significant risk • 25%
No significant risk found • 25%
Inconclusive results • 25%
Study retracted • 25%
Published study results in medical journals or official announcements
Story
Novo Nordisk's Ozempic Label Update Approved by EMA for Risk Reduction of Kidney Disease-Related Events Amid Vision Loss Study
Dec 13, 2024, 01:46 PM
Novo Nordisk's diabetes drug Ozempic has received a positive opinion from the European Medicines Agency (EMA) to update its label, which will now reflect the drug's potential to reduce the risk of kidney disease-related events. This approval follows a study that found a small number of patients experienced vision loss linked to Ozempic, corroborating previous research from Harvard University. Concurrently, Eli Lilly's Mounjaro is gaining popularity among Britons seeking obesity treatments, surpassing Novo Nordisk's Wegovy in preference. The recent findings suggest that while Ozempic may offer significant benefits for weight management and diabetes, its association with rare vision loss raises important safety considerations for patients and healthcare providers alike.
View original story
Similar markets
No publication • 25%
Confirms link • 25%
Refutes link • 25%
Inconclusive • 25%
Investigation ongoing • 25%
No causative link found • 25%
Inconclusive results • 25%
Causative link confirmed • 25%
Decrease from 2024 levels • 25%
Stable compared to 2024 • 25%
Increase from 2024 levels • 25%
Data not available • 25%
25-49% reduction • 25%
70% or more reduction • 25%
Less than 25% reduction • 25%
50-69% reduction • 25%
Approve distribution city-wide • 25%
No decision made • 25%
Approve limited distribution • 25%
No distribution approved • 25%
Slightly effective • 25%
Moderately effective • 25%
Highly effective • 25%
Not effective • 25%
Safety label update • 25%
Other regulatory actions • 25%
Product recall • 25%
No action taken • 25%
Stricter guidelines issued • 25%
Guidelines under review • 25%
Guidelines relaxed • 25%
No changes • 25%